This effect was not present among patients without a GATA2 deficiency and GATA2 mRNA expression remained stable during disease progression (mean ± SD 0.09223 ± 0.04805 in MDS-EB and 0.1055 ± 0.04004 in RCC, Figure 1D). The gene discussed is GATA2; the disease is epidermolysis bullosa.